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Objective: Trastuzumab (Herceptin®), a recombinant, humanized, monoclonal antibody targeting 
HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from 
developed countries showed that trastuzumab was cost-effective; but there are few evidences in 
developing countries. This study assesses the cost-effectiveness of adjuvant trastuzumab treatment 
in Colombia.
Methods: A Markov health-state transition model was built to estimate clinical and economic outcomes 
in HER2-positive breast cancer with or without 12 months trastuzumab adjuvant chemotherapy over a 
lifetime perspective with annual transition cycles. The model incorporated five health states (disease-
free, local recurrence, distant recurrence, cardiac failure, and death). Baseline event rates and 3-year 
hazard ratio (HR=0.51, IC 95% 0.44–0.59; p<0.0001) were derived from 4-year follow up of the N9831 
and NSABP B-31 trial. Costs and utility weights were obtained from the literature and were discounted 
by 5% annually.
Results: The model showed that the utilization of adjuvant trastuzumab treatment in early breast 
cancer can prolong 0.80 quality-adjusted life-years (QALY), compared with standard chemotherapy, an 
incremental cost-effectiveness ratio (ICER) of US$ 71,491 per QALY gained.
Conclusion: The results suggest that 1-year adjuvant Trastuzumab treatment is not cost-effective in 
Colombia, using the definition of WHO cost-effectiveness threshold of 3 times GDP per capita. 
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Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2-
positivo en Colombia
Introducción. El trastuzumab es un anticuerpo monoclonal de reconocida efectividad para el 
tratamiento en mujeres con cáncer de mama positivo para HER2. Sin embargo, la mayoría de estudios 
de costo-efectividad se han llevado a cabo en países desarrollados. 
Objetivo. Determinar el costo-efectividad del tratamiento adyuvante con trastuzumab en mujeres con 
cáncer de mama HER2+ en Colombia.
Materiales y métodos. Se construyó un modelo de Markov, con ciclos de transición anuales y 
desde la perspectiva del pagador, para estimar los resultados clínicos y económicos derivados de 
la administración de trastuzumab en mujeres con HER2 positivo. El modelo incorpora cinco estados 
de transición: libre de enfermedad, recurrencia local, metástasis, falla cardiaca y muerte. La tasa de 
eventos y la razón de tazas instantáneas (0,51; IC95% 0,44-0,59; p<0,0001) se derivaron del reporte a 
cuatro años de los ensayos clínicos controlados N9831 y NSABP B-31. Los costos y las utilidades se 
estimados a partir de la literatura científica, utilizando una tasa de descuento del 5 % anual.
Resultados. El modelo revela que la utilización de trastuzumab como tratamiento adyuvante prolonga 
la expectativa de vida ajustada por calidad en 0,8 años, en comparación con la quimioterapia sin 
trastuzumab; a una razón de costo efectividad incremental (sic.) de US$ 71.491 por año de vida ganado 
ajustado por calidad de vida.
Conclusión. El tratamiento con trastuzumab durante un año no es costo-efectivo en Colombia, 
utilizando la definición de costo-efectividad de la OMS de menos de dos a tres veces el PIB per cápita 
por año de vida ganado ajustado por calidad de vida. 
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Introduction
Breast cancer is the first leading cause of cancer 
death in women in Colombia .The adjusted mortality 
rate of breast cancer was 9.5 per 100,000 females 
and there was an uptrend either in the morbidity and 
mortality during the last years. Breast cancer has 
become in the most common cancers for women in 
Colombia, and other developing countries. 
Trastuzumab (Herceptin®), a recombinant, 
humanized, monoclonal antibody targeting HER2 
is well established as an effective treatment for 
HER2-positive breast cancer. It was notable that 
trastuzumab significantly reduced the risks of cancer 
local recurrence and metastasis and can prolong 
survival. Though the cost of trastuzumab treatment 
is high; and this drug has been recommended 
as adjuvant treatment for HER2-positive breast 
cancer. Evidence from other countries showed 
that trastuzumab was cost-effective in adjuvant 
treatment for early breast cancer; but there are 
few evidence of cost-effectiveness analyses in 
developing countries  based on the 4-year follow-
up data of the North Central Cancer Treatment 
Group (NCCTG) N9831 and the National Surgical 
Adjuvant Breast and Bowel Project (NSABP) and 
HERA trial  where the magnitudes of improvement 
in disease-free survival were decreased and cost 
effectiveness of adjuvant trastuzumab remains 
uncertain. 
This drug has a relative high treatment cost 
respect to others current drugs in breast cancer 
and there are concerns whether trastuzumab have 
an adequate equilibrium between cost and it´s 
benefits especially in developing counties  where 
cost-effectiveness and outcomes evidence tend 
to be vital for policymakers to make a tradeoff 
between limited financial resources and equitable 
access. Therefore, this cost-effectiveness analysis 
is designed to increase the economic evidence, of 
adjuvant trastuzumab therapy, to support decision-
making from the perspective of health-care payers.
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Patients and methods
A Markov model chain , programmed in a TreeAge 
Pro 2009®,  was developed to estimate the costs 
and outcomes of 12 months of adjuvant trastuzumab 
after chemotherapy for HER2-positive breast cancer, 
compared to standard chemotherapy in a hypothetical 
cohort of ‘‘typical’’ patient enrolled in the NCCTG 
and NSABP trials  —a 50-year-old woman. Patients 
were eligible if they had invasive breast cancer 
resected by lumpectomy or mastectomy and axillary 
dissection with pathologically involved axillary nodes 
(amended in NCCTG N9831 to allow patients with 
high-risk, node-negative disease). The tumor had to 
be HER2-positive (immunohistochemistry score of 3+ 
or fluorescence in situ hybridization [FISH]-positive) 
and had to be verified centrally [NCCTG N9831] or 
by an approved laboratory [NSABP B-31]). Patients 
had to have normal hematologic, hepatic, and renal 
function, and normal left ventricular ejection fraction, 
as assessed by multigated acquisition scan or 
echocardiogram. Patients were excluded when they 
had locally advanced or distant disease, had received 
prior anthracycline or taxane therapy, had significant 
sensory or motor neuropathy,or had past or active 
cardiac disease. Clinical data and the treatment 
protocol were based on the results of the NCCTG 
N9831 and NSABP B-31 and HERA trial. Five health 
states were defined in the progression of breast 
cancer: disease-free state (DFS), local recurrence 
(local and contralateral), metastasis, cardiac event, 
and death (see Fig. 1). The analysis was run from 
a lifetime perspective. The cycle length was 1 year. 
Costs and QALYs were both discounted in the base 
case analysis by 5% annually. All assumptions used 
in the model are outlined in table 1.
Clinical data
According to the 4-year follow up of N9831 and 
NSABP B-31 trials assessed the efficacy and 
safety of adding 52 weeks of trastuzumab to 
standard anthracycline/taxane-based chemotherapy 
(doxorubicin plus cyclophosphamide  followed by 
paclitaxel). The adjusted hazard ratio for recurrence 
in the trastuzumab group, compared with the 
observation group, was 0.51; (95% confidence 
interval: 0.44–0.59; p<0·0001). The loading dose of 
Trastuzumab in the model was 4 mg per kilogram 
weight and 2 mg per kilogram weekly. The specific 
transition probabilities of disease progression were 
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retrieved from the literature  (see table 2). The 
clinical benefit of trastuzumab was assumed to last 
for the first 5 years . Thereafter, the risk for recurrent 
and metastatic disease in the trastuzumab group 
was assumed to be the same as in the observation 
group. The utilities associated with different health 
states were derived from published literature 
(see table 3). The baseline rate and the relative 
risk of cardiac toxicity with adjuvant trastuzumab 
Figure 1 Key health states and their transitions
Rem: disease-free state, RLR: local recurrence (local and 
contralateral) , RMD: metastasis 
ICC: cardiac event, MCM: death from breast cancer, MOC: 
death from all other causes
were derived from the incidence of symptomatic 
congestive heart failure from the literature. 
Costs
The analysis perspective was that of health-care 
payers, and we calculated only the direct medical 
costs (see table 4). Neither indirect costs (example: 
work loss) nor direct non-medical costs (example: 
transportation) were considered. Management 
costs for local and distant cancer recurrences 
(hormonal therapy, chemotherapy, radiotherapy, 
supportive care), costs of managing cardiotoxicity 
and costs of Trastuzumab in the adjuvant setting- 
including HER2/neu screening, acquisition costs, 
drug administration, supportive medications, and 
patient management - were taken from earlier cost 
studies, adjusted for current inflation in Colombia 
(2010), and National Health Reference Price List 
(SOAT 2010).The cost impact of longer or shorter 
palliative Trastuzumab therapy was tested in a one-
way sensitivity analysis. All costs were adjusted 
to 2010 US dollars (Currency rate: US$ 1.00 = 
COP$ 2,000).The primary result is indicated as the 
incremental cost per incremental quality adjusted 
life-year-gained (QALYs). 
Sensitivity Analysis
We conducted sensitivity analyses with Monte-Carlo 
simulation method to understand the key drivers and 
general sensitivity of the model.  We used this kind 
of analysis because it let us vary simultaneously, 
across 10,000 simulations, different variables of 
model according to specific probability distributions. 
The following variables were assessed: utility 
values, discounting rate, transition probabilities, 
total cost by health state; hazard ratio, drug price 
and, efficacy period of trastuzumab. Because the 
model is a synthesis of a number of data sources, 
the short-term overall survival estimates were 
compared with overall survival results reported by 
the clinical trials to assess the internal validity of 
the model. The discount-rate range for sensitivity 
was 0-10%. Because none of the cost studies 
reported the variance of their mean cost estimates, 
the probabilistic modeling assumed a log normal 
distribution with a standard deviation of 0.25 for all 
cost parameters.  
Results
The mean of life years was 9.35 years with 
trastuzumab and 8.53 years without trastuzumab, 
an increment of 0.82 years. Incremental QALY 
of 0.80 years was generated with trastuzumab 
treatment (see table 5).
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The discounted lifetime medical expenditure 
(discount rate of 5%) was US$ 132,361 per patient 
treated with trastuzumab and US$ 75,315 without 
trastuzumab treatment. This result in an incremental 
cost-effectiveness ratio (ICER) for trastuzumab 
treatment of US$ 71,491 per QALY gained.
Sensitivity analysis
One-way sensitivity analyses of parameters in 
the model showed that cost-effectiveness of 
trastuzumab was sensitive to the discount rate 
- ICER with discount rate of 0% of US$ 39,724 
and US$ 115,132 with discount rate of 10%-; and 
duration of clinical benefit - ICER with 10 years of 
duration of clinical benefit of US$ 46,397.
Other one-way sensitivity analyses for total cost 
by health state, utility by health state and transition 
probabilities, price and HR of trastuzumab, showed 
little change. The acceptability curve is shown in Figure 
2. The probability that the ICER of 1-year Trastuzumab 
was less than US$ 15,000 was 12.4%. (Using the 
WHO cost-effectiveness threshold of 3 times GDP per 
capita: US$ 15,000 in Colombia, 2010.
Table 1. Model assumptions 
1.  There were no cancer recurrences beyond year 20 of the model.
2.  The age of the cohort at entry into the model was 49 years.
3.  The clinical benefit of trastuzumab was assumed to last for the first 5 years [13]. Thereafter, the risk for recurrent and metastatic 
disease in the trastuzumab group was assumed to be the same as in the observation group 
4.  The age-specific death rates for disease-free state and recurrence states were assumed to be the same as that of the females 
population, taken from the Colombian National Population Statistics. 
5.  Trastuzumab is used for 50% of patients in metastatic state who have already been administered trastuzumab as adjuvant 
therapy .
6.  Adjuvant trastuzumab patients experience cardiotoxicity within the first year of treatment, and this drug adverse effect is 
reversible . 
7.  Because there were no cardiac deaths in the trastuzumab arm of  clinical trials, the model assumed no additional mortality as 
a result of cardiotoxicity
8.  Recurrent loco-regional disease and contralateral breast cancers were combined as local recurrences.
9.  Patients could suffer only one local recurrence. Any subsequent recurrences were distant. 
10.  All deaths by breast cancer occur in women with distant recurrence
11.  The patient does not suffer from other comorbidities at baseline.
Table 2 .Transition probabilities between health states 
From to Transition  CI 95% Distribution
  probability
Local recurrence DFS 0.1000 0.06 0.14  Beta
Local recurrence Metastasis 0.0785 0.0390 0.1059
Metastasis DFC 0.2950 0.1770 0.7000
Cardiac events Local recurrence 0.0294 0.0087 0.0350
Cardiac events Metastasis 0.0785 0.0390 0.1059
DFS Cardiac events 0.0053 0.0028 0.0101
DFS Local recurrence 0.0294 0.0087 0.0350
DFS Metastasis 0.0785 0.0390 0.1059
DFS: disease-free state
DFC : death from cancer
Table 3. Utility value of different health states for Markov model 
Utility value CI 95% Distribution
DFS 0.847 (0.807, 0.886) Beta
Local  0.810 (0.760, 0.870)
recurrence 
Metastasis  0.484 (0.426, 0.542)
Cardiac events 0.700 (0.650, 0.750)
DFS: disease-free state
Table 4. Total cost 
Health state Total Cost 
 (US$)
Adjuvant Trastuzumab 4,219
1 year in symptomatic cardiac events 1,237
1 year in local recurrence 8,588
1 year in metastatic state 52,093
1 year in DFS 1,103
DFS: disease-free state
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Figure 2. Cost-effectiveness acceptability curve
Table 5.  Cost-effectiveness analysis
 Without trastuzumab Trastuzumab Difference ICER (US$)
Lifetime medical expenditure (US$) 75 315 132 361 57 046 
Life years gained 8.53 9,35 0.82 69 701
QALYs gained 6.83 7.62 0.80 71 491
To test external validity, the model results for no 
Trastuzumab were compared with survival at 3 
years in control arms of N9831 and NSABP B-31 
and HERA trial. N9831 and NSABP B-31 and HERA 
trial reported survival of 92% and 91% respectively 
and our model predicted survival of 88%. 
Discussion 
The 1-year adjuvant trastuzumab treatment is not 
cost effective in Colombia. Since Colombia does 
not have a threshold that represents the willingness 
to pay (WTP) per unit of effectiveness (LYG or 
QALY), the ICER results per QALY were evaluated 
by using the reference corresponds to the World 
Health Organization (WHO) recommendation 
(three times the GDP per capita). The uncertainty 
of threshold levels in developing countries such as 
Colombia creates some controversies and 3 times 
the GDP per capita per QALY gained might differ 
from the real willingness to pay by decision makers 
to Colombia. Some authors recommends that the 
threshold for WTP should be treated as a range 
of cost and the probability of rejection should be 
determined based on the estimated acceptance 
curve. In our study trastuzumab treatment had only 
a 12.4% likelihood of meeting a $15,000 per QALY 
threshold in Colombia. Our model yielded similar 
results to other analyses in Colombia. Castillo 
using a Markov model with nine key health states 
in 2008, from the perspective of the Colombian 
National Cancer Institute (direct payer), found that 
adjuvant trastuzumab is not cost-effective based 
on the interim clinical data from N9831 and NSABP 
B-31, with an ICER per LYG (US$ 30,574). As well, 
our findings are similar to recent study of CE of 
Trastuzumab in seven countries in Latin-America 
, using four health states in 2011 from health care 
sector perspective, where incremental CE ratios 
ranged from US$ 42,104 to $ 110,283 per QALY 
with a 0% of probability that trastuzumab was CE 
if willingness-to-pay threshold is three GDP per 
capita.  
Increasing medical costs are becoming a major 
issue in developing countries. The acquisition cost 
of trastuzumab, like many newer oncology drugs, 
is relatively high respect to other breast cancer 
drugs and this is particularly evident in developing 
countries with highest drug prices  relative to 
their mean per capita income; increasing the gap 
between the cost of new and current therapies 
increasing probability of payment rejection based 
in QALY threshold. This drug have been included 
in National Essential Medicine List and national 
guidelines of breast cancer despite of previously 
and recent evidence of not cost effectiveness of 
this drug not only in Colombia and other countries 
of Latin-America using  a WHO recommendation of 
willingness to pay (WTP) per unit of effectiveness 
(LYG or QALY), of three times the GDP per capita. 
In our analyses, CE was particularly sensitive to 
the duration of carryover benefit for trastuzumab 
beyond the 5-year efficacy results reported by the 
updated trials. The CE for adjuvant trastuzumab, 
was US$ 60,246 and US$ 43,397 per QALY 
gained for the 6- and 10-year benefit scenarios, 
respectively. Skedgel applied efficacy estimates 
from the updated HERA study found a ICER  of CDN$ 
72,292  per QALY gained based on 5-year duration 
of benefit, and CDN$ 127,862 per QALY with 3-year 
duration of benefit over a 25-year analysis horizon. 
Also, a recent updated  cost-effectiveness analysis 
from the UK perspective, found that the cost-
effectiveness of trastuzumab was highly sensitive 
to the estimated duration of treatment benefit 
assuming the hazard ratio for disease-free survival 
was 0.63. The difference in results between the 5- 
416
Biomédica 2013;33:411-7Buendía JA,  Vallejos C, Pichón-Rivière A
and 10-year benefit scenarios in our analysis, and 
before papers highlights the need for longer follow-
up in clinical trials to define the true duration of 
adjuvant trastuzumab benefit. An especial attention 
must be placed on discount rate; in our study CE 
was particularly sensitive to discount rate .Since 
explicit stamens for Latin American countries 
were not available, we used parameters used 
and recommended by international literature . In 
this sense, in our analysis using a higher discount 
rate (10%) or lower discount rate (0%) could not 
change our results and trastuzumab is considered 
non-cost-effective using the threshold corresponds 
to the WHO recommendation (three times the GDP 
per capita).
There were several limitations to our analysis. First, 
we used UK utilities because in Colombia there 
are no health-related quality of life data for breast 
cancer patients. Nevertheless, one-way sensitivity 
analyses for utilities associated with different health 
states showed little change. Second, our analysis 
was based on estimates of efficacy under controlled 
conditions rather than effectiveness in actual clinical 
practice. It is likely that the observed clinical benefit 
of adjuvant trastuzumab in routine clinical practice 
will be less favorable than that observed in clinical 
trials. We took a direct payer rather than a societal 
cost perspective that would include costs such as 
lost productivity and caregiver time. Cardiac event 
was modeled as one of the five mutually exclusive 
health states similar to other studies. We assumed 
that medical treatment for cardiac events was 
carried out for 1 year, as trastuzumab cardiotoxicity 
is usually reversible. To date, in all available studies 
with adjuvant T treatment, no death due to heart 
failure occurred; hence, mortality due to side-effects 
was assumed to be zero. In conclusion 1-year 
adjuvant trastuzumab treatment is not cost-effective 
in Colombia, using the definition of WHO cost-
effectiveness threshold of 3 times GDP per capita.
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